235 related articles for article (PubMed ID: 11103942)
21. Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines.
Kim SK; Su LK; Oh Y; Kemp BL; Hong WK; Mao L
Oncogene; 1998 Jan; 16(1):89-93. PubMed ID: 9467947
[TBL] [Abstract][Full Text] [Related]
22. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer.
Cheney IW; Johnson DE; Vaillancourt MT; Avanzini J; Morimoto A; Demers GW; Wills KN; Shabram PW; Bolen JB; Tavtigian SV; Bookstein R
Cancer Res; 1998 Jun; 58(11):2331-4. PubMed ID: 9622068
[TBL] [Abstract][Full Text] [Related]
23. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Kurose K; Zhou XP; Araki T; Cannistra SA; Maher ER; Eng C
Am J Pathol; 2001 Jun; 158(6):2097-106. PubMed ID: 11395387
[TBL] [Abstract][Full Text] [Related]
24. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells.
Davies MA; Kim SJ; Parikh NU; Dong Z; Bucana CD; Gallick GE
Clin Cancer Res; 2002 Jun; 8(6):1904-14. PubMed ID: 12060635
[TBL] [Abstract][Full Text] [Related]
25. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.
Bianco R; Shin I; Ritter CA; Yakes FM; Basso A; Rosen N; Tsurutani J; Dennis PA; Mills GB; Arteaga CL
Oncogene; 2003 May; 22(18):2812-22. PubMed ID: 12743604
[TBL] [Abstract][Full Text] [Related]
26. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
27. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.
Haas-Kogan D; Shalev N; Wong M; Mills G; Yount G; Stokoe D
Curr Biol; 1998 Oct; 8(21):1195-8. PubMed ID: 9799739
[TBL] [Abstract][Full Text] [Related]
28. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Tsao H; Zhang X; Fowlkes K; Haluska FG
Cancer Res; 2000 Apr; 60(7):1800-4. PubMed ID: 10766161
[TBL] [Abstract][Full Text] [Related]
29. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
Teng DH; Hu R; Lin H; Davis T; Iliev D; Frye C; Swedlund B; Hansen KL; Vinson VL; Gumpper KL; Ellis L; El-Naggar A; Frazier M; Jasser S; Langford LA; Lee J; Mills GB; Pershouse MA; Pollack RE; Tornos C; Troncoso P; Yung WK; Fujii G; Berson A; Steck PA
Cancer Res; 1997 Dec; 57(23):5221-5. PubMed ID: 9393738
[TBL] [Abstract][Full Text] [Related]
30. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers.
Cairns P; Evron E; Okami K; Halachmi N; Esteller M; Herman JG; Bose S; Wang SI; Parsons R; Sidransky D
Oncogene; 1998 Jun; 16(24):3215-8. PubMed ID: 9671402
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of multiple drug resistance in human bladder cancer cell lines.
Shinohara N; Liebert M; Wedemeyer G; Chang JH; Grossman HB
J Urol; 1993 Aug; 150(2 Pt 1):505-9. PubMed ID: 8100862
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.
Saga Y; Mizukami H; Suzuki M; Kohno T; Urabe M; Ozawa K; Sato I
Clin Cancer Res; 2002 May; 8(5):1248-52. PubMed ID: 12006545
[TBL] [Abstract][Full Text] [Related]
33. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
[TBL] [Abstract][Full Text] [Related]
34. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression.
Huang H; Cheville JC; Pan Y; Roche PC; Schmidt LJ; Tindall DJ
J Biol Chem; 2001 Oct; 276(42):38830-6. PubMed ID: 11495901
[TBL] [Abstract][Full Text] [Related]
35. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways.
Weng L; Brown J; Eng C
Hum Mol Genet; 2001 Feb; 10(3):237-42. PubMed ID: 11159942
[TBL] [Abstract][Full Text] [Related]
36. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.
Furnari FB; Huang HJ; Cavenee WK
Cancer Res; 1998 Nov; 58(22):5002-8. PubMed ID: 9823298
[TBL] [Abstract][Full Text] [Related]
37. PTEN/MMAC1 overexpression decreases insulin-like growth factor-I-mediated protection from apoptosis in neuroblastoma cells.
van Golen CM; Schwab TS; Ignatoski KM; Ethier SP; Feldman EL
Cell Growth Differ; 2001 Jul; 12(7):371-8. PubMed ID: 11457734
[TBL] [Abstract][Full Text] [Related]
38. The expanding role of PTEN in neoplasia: a molecule for all seasons? Commentary re: M. A. Davies, et al., Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin. Cancer Res., 8: 1904-1914, 2002.
Fernandez M; Eng C
Clin Cancer Res; 2002 Jun; 8(6):1695-8. PubMed ID: 12060605
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of PTEN/MMAC1 and decreased activation of Akt in human papillomavirus-infected laryngeal papillomas.
Zhang P; Steinberg BM
Cancer Res; 2000 Mar; 60(5):1457-62. PubMed ID: 10728713
[TBL] [Abstract][Full Text] [Related]
40. Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens.
Liu J; Babaian DC; Liebert M; Steck PA; Kagan J
Mol Carcinog; 2000 Nov; 29(3):143-50. PubMed ID: 11108659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
